Abstract: The present invention relates to the use of a peptide having the amino acid sequence NH2-VCVLAHHFGKEFTPPVQAAYQKVVAGVANALAHKYH-COOH as well as variants, derivatives and fragments of the peptide for the treatment of viral diseases.

Abstract: Disclosed is an intracardiac blood pump comprising a driving part and a pump part between which discharge ports are located. The pump part is connected to a flexible screen which catches the axially discharged flow and deflects the same in an axial direction. The delivery rate of the pump is increased by preventing impact losses and swirls at the discharge ports.

Abstract: The invention relates to oligomeric peptides with biological activity against HIV infection having the amino acid sequence (Z1-LE-X1-IP—X2—X3—X4—P—X5—X6—X7—X8—X9—X10—K—X11—X12—X13—X14—X15-Z2)n, wherein n indicates the number of monomeric peptide chains, whereby n is 2, 3 or 4; X1 is a lysine, alanine, or aspartic acid; X2 is a cysteine, methionine or isoleucine; X3 is a serine, cysteine, lysine or glycine; X4 is an isoleucine, alanine, phenylalanine or cysteine; X5 is a proline, D-proline or a substituted L- or D-proline; X6 is a cysteine or glutamic acid; X7 is an amino acid with a hydrophobic or an aromatic side chain or cysteine; X8 is an amino acid with a hydrophobic or an aromatic side chain or cysteine; X9 is an amino acid with an aromatic side chain; X10 is a glycine, alanine or asparagine; X11 is a proline, aspartic acid, octahydroindolyl-2-carboxylic acid or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; X12 is a phenylalanine, alanine, glycine, glutamic acid or D-1,2,3,4-tetrahyd

Abstract: The invention relates to peptides with biological activity against infection having the amino acid sequence Z1-LE-X1-IP-X2-X3-X4-P-X5-X6-X7-X8-X9-X10-K-X11-X12-X13-X14-X15-Z2, wherein X1 is a lysine, alanine, or aspartic acid; X2 is a cysteine, methionine or isoleucine; X3 is a serine, cysteine, lysine or glycine; X4 is an isoleucine, alanine, phenylalanine or cysteine; X5 is a proline, D-proline or a substituted L- or D-proline; X6 is a cysteine or glutamic acid; X7 is an amino acid with a hydrophobic or an aromatic side chain or cysteine; X8 is an amino acid with a hydrophobic or an aromatic side chain or cysteine; X9 is an amino acid with an aromatic side chain; X10 is a glycine, alanine or asparagine; X11 is a proline, aspartic acid, octahydroindolyl-2-carboxylic acid or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; X12 is a phenylalanine, alanine, glycine, glutamic acid or D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; X13 is an amino acid with a hydrophobic or an aromatic side chain; X14 is a

Abstract: A peptide having the following amino acid sequence: Z1-LEAIPMSIPPEVKFNKPFVF-Z2 (VIRIP) and its biologically active fragments and/or variants and/or derivatives, especially amidated, acetylated, sulfated, polyethylene glycol (PEG) modified, phosphorylated and/or glycosylated derivatives, and peptides obtainable by multiple synthesis which have the biological activity of VIRIP; wherein Z1 and Z2 are independently a sequence of from 0 to 10 amino acid residues, and if Z1 or Z2=zero amino acid residues, then Z1=H and/or Z2=COOH.

Abstract: The present invention is related to newly identified compounds, polynucleotide sequences encoding the amino acid sequences of the compounds, as well as agonists, antagonists or inhibitors of the compounds for chemokine receptors, especially the CCR-5 receptor and their use in the field of diagnostics and therapeutics involving the chemokine receptors.